Organigram Clocks Highest Quarterly Net Revenue In Q1

Loading...
Loading...

Organigram Holdings Inc OGI has posted Q1 FY22 net revenue of $30.4 million, the highest quarterly net revenue in the company's history at 22% growth sequentially and 57% Y/Y.

  • The increase was primarily due to increased adult-use recreational revenue and international revenue, partly offset by lower average selling price due to product mix and a decrease in medical revenue.
  • Q1 FY22 cost of sales increased by 20% to $27.9 million, primarily due to the increase in sales volume in the adult-use recreational market.
  • Adjusted gross margin improved to $5.5 million, or 18% of net revenue, compared to $1.9 million, or 10% last year. 
  • The improvement was largely due to reduced cultivation costs partially offset by a shift in the sales mix to value-priced products and brands with a lower ASP.
  • The company posted a narrower adjusted EBITDA loss of $(1.9) million compared to $(5.7) million a year ago.
  • Net loss for the quarter also decreased to $(1.3) million from a loss of $(34.3) million a year ago.
  • Lower losses are attributable to higher gross margin and fair value adjustments on biological assets and inventories sold.
  • Net cash used in operating activities was $9.3 million. 
  • Outlook: Organigram currently anticipates Q2 net revenue significantly higher than the prior year and expects to see a sequential improvement in adjusted gross margins in Q2.
  • Price Action: OGI shares are trading 5.78% higher at $1.83 during the premarket session on the last check Tuesday.
Loading...
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLong IdeasNewsPenny StocksGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefscannabis stockswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...